Currently, COVID-19 is one of the most pressing healthcare problems across the world. With no definitive pharmacological guidelines, multiple drugs were used to treat critical patients with little success. of Tocilizumab, a monoclonal antibody has shown some role in the treatment of Covid-19 infection. The study was a cross-sectional prospective observational study. It was conducted in the COVID-19 Intensive Care Unit (ICU) of Liaquat National Hospital and Medical College, and National Medical Centre Karachi. The study was conducted from 15th June 2020 to 31st July 2020. Objective of the study was to compare the outcomes of severe to critical COVID-19 patients with established Cytokine release Syndrome (CRS), who received Tocilizumab with the group received Tocilizumab followed by intravenous immunoglobulins (IVIG). Two groups were made with one receiving Tocilizumab alone while the other received IVIG after Tocilizumab. Comparison was then made based on frequency of mortality as well the need of mechanical ventilation and its range of days. In results 4 (15.4%) patients in Tocilizumab only group died while Tocilizumab followed by IVIG treated group had 10 (38.46%) deaths. 20 (76.9%) patients needed mechanical ventilation in Tocilizumab only group while Tocilizumab followed by IVIG treated group consisted of 23 (88.46%) patients. This concludes that the group with only Tocilizumab therapy has better outcome as compare to the group who received both Tocilizumab and intravenous immunoglobulins.
| Published in | International Journal of Infectious Diseases and Therapy (Volume 6, Issue 1) |
| DOI | 10.11648/j.ijidt.20210601.15 |
| Page(s) | 37-40 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
COVID-19, Coronavirus, Tocilizumab, Immunoglobulin
| [1] | World Health Organization (WHO) WHO; Geneva, Switzerland: 2020. Coronavirus disease 2019 (COVID-19). Situation report - 51. https://www.who.int/docs/default- source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19. pdf?sfvrsn=1ba62e57_10 [Accessed 1 October 2020] J. Clerk Maxwell, A Treatise on Electricity and Magnetism, 3rd ed., vol. 2. Oxford: Clarendon, 1892, pp. 68–73. |
| [2] | Worldometers. COVID-19 Coronavirus pandemic. Available at https://www.worldometers.info/coronavirus [Accessed 1 October 2020]. |
| [3] | Chen J, Lu H, Melino G, et al. COVID-19 infection: the China and Italy perspectives. Cell Death Dis. 2020; 11 (6): 438. Published 2020 Jun 8. doi: 10.1038/s41419-020-2603-0. |
| [4] | Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020 Feb 29; 14 (2): 125-128. doi: 10.3855/jidc.12600. PMID: 32146445. |
| [5] | Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 doi: 10.1001/jama.2020.4683. |
| [6] | Zhang Z, Yao W, Wang Y, Long C, Fu X. Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources. J Infect. 2020; 81 (1): 147-178. doi: 10.1016/j.jinf.2020.03.018. |
| [7] | Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020; 53 (3): 436-443. doi: 10.1016/j.jmii.2020.03.034. |
| [8] | Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf 2020; 43 (8): 691-698. doi: 10.1007/s40264-020-00976-7. |
| [9] | Ramireddy A, Chugh H, Reinier K, et al. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc. 2020; 9 (12): e017144. doi: 10.1161/JAHA.120.017144. |
| [10] | Zhang XL, Li Z. M, Ye JT, et al. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives [published online ahead of print, 2020 Sep 23]. Acta Pharmacol Sin. 2020; 1-10. doi: 10.1038/s41401-020-00519-x. |
| [11] | Sharma A. Chloroquine paradox may cause more damage than help fight COVID-19. Microbes Infect. 2020; 22 (4-5): 154-156. doi: 10.1016/j.micinf.2020.04.004. |
| [12] | Wong C. K., Lam C. W. K., Wu A. K. L. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136 (1): 95–103. |
| [13] | Bhatraju PK, Ghassemieh BJ, Nichols M. Covid-19 in critically ill patients in the Seattle region–case series. N Engl J Med. 2020 doi: 10.1056/NEJMoa2004500. published online March 30. |
| [14] | Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007016. published online April 10. |
| [15] | Holshue ML, DeBolt C, Lindquist S. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382: 929–936. |
| [16] | Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol. 2020; 11: 1333. Published 2020 Aug 28. doi: 10.3389/fphar.2020.01333 |
| [17] | Mastroianni A, Greco S, Apuzzo G, et al. Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: an observational cohort study. EClinical Medicine. 2020. doi. org/10.1016/j.eclinm.2020.100410. |
| [18] | Radbel J, Narayanan N, Bhatt PJ. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. Chest. 2020; 158 (1): e15-e19. doi: 10.1016/j. chest.2020.04.024. |
| [19] | Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013 Mar; 13 (3): 176-89. doi: 10.1038/nri3401. Epub 2013 Feb 15. PMID: 23411799. |
| [20] | Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases [published correction appears in Clin Exp Immunol 1992 May; 88 (2): 373]. Clin Exp Immunol. 1991; 86 (2): 192-198. doi: 10.1111/j.1365-2249.1991.tb05794.x. |
| [21] | Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020; 96: 467-474. doi: 10.1016/j.ijid.2020.05.055. |
| [22] | Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician' s perspective. Diabetes Metab Syndr. 2020; 14 (5): 971-978. doi: 10.1016/j. dsx.2020.06.054. |
| [23] | Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI) – diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011; 51 (1): 61–70. |
| [24] | Takashi T, Hiroki M, Kiyohide F. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Diseases. 2015; 61 (3): 385–392. |
| [25] | Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects. PLoS Med. 2006; 3 (9): e343. |
| [26] | Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. J Infect Publ Health. 2017; 11 (1): 9–17. |
| [27] | Ivan F. N, Hung Hyperimmune IV Immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest. 2013; 144 (2): 464–473. |
| [28] | Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020; 81 (2): 318-356. doi: 10.1016/j.jinf.2020.03.044. |
| [29] | Cao W, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7 (3): ofaa102. |
| [30] | Lanza M, Polistina GE, Imitazione P, et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. IDCases. 2020; 21: e00794. Published 2020 May 16. doi: 10.1016/j.idcr.2020.e00794. |
APA Style
Syeda Rida-e-Zehra, Shamim Kausar, Anum Latif, Samar Abbas Jaffri, Syeda Namayah Fatima Hussain, et al. (2021). Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease. International Journal of Infectious Diseases and Therapy, 6(1), 37-40. https://doi.org/10.11648/j.ijidt.20210601.15
ACS Style
Syeda Rida-e-Zehra; Shamim Kausar; Anum Latif; Samar Abbas Jaffri; Syeda Namayah Fatima Hussain, et al. Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease. Int. J. Infect. Dis. Ther. 2021, 6(1), 37-40. doi: 10.11648/j.ijidt.20210601.15
AMA Style
Syeda Rida-e-Zehra, Shamim Kausar, Anum Latif, Samar Abbas Jaffri, Syeda Namayah Fatima Hussain, et al. Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease. Int J Infect Dis Ther. 2021;6(1):37-40. doi: 10.11648/j.ijidt.20210601.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijidt.20210601.15,
author = {Syeda Rida-e-Zehra and Shamim Kausar and Anum Latif and Samar Abbas Jaffri and Syeda Namayah Fatima Hussain and Irfan Ahsan and Muhammad Rafay and Pirih Bhatti},
title = {Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease},
journal = {International Journal of Infectious Diseases and Therapy},
volume = {6},
number = {1},
pages = {37-40},
doi = {10.11648/j.ijidt.20210601.15},
url = {https://doi.org/10.11648/j.ijidt.20210601.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijidt.20210601.15},
abstract = {Currently, COVID-19 is one of the most pressing healthcare problems across the world. With no definitive pharmacological guidelines, multiple drugs were used to treat critical patients with little success. of Tocilizumab, a monoclonal antibody has shown some role in the treatment of Covid-19 infection. The study was a cross-sectional prospective observational study. It was conducted in the COVID-19 Intensive Care Unit (ICU) of Liaquat National Hospital and Medical College, and National Medical Centre Karachi. The study was conducted from 15th June 2020 to 31st July 2020. Objective of the study was to compare the outcomes of severe to critical COVID-19 patients with established Cytokine release Syndrome (CRS), who received Tocilizumab with the group received Tocilizumab followed by intravenous immunoglobulins (IVIG). Two groups were made with one receiving Tocilizumab alone while the other received IVIG after Tocilizumab. Comparison was then made based on frequency of mortality as well the need of mechanical ventilation and its range of days. In results 4 (15.4%) patients in Tocilizumab only group died while Tocilizumab followed by IVIG treated group had 10 (38.46%) deaths. 20 (76.9%) patients needed mechanical ventilation in Tocilizumab only group while Tocilizumab followed by IVIG treated group consisted of 23 (88.46%) patients. This concludes that the group with only Tocilizumab therapy has better outcome as compare to the group who received both Tocilizumab and intravenous immunoglobulins.},
year = {2021}
}
TY - JOUR T1 - Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease AU - Syeda Rida-e-Zehra AU - Shamim Kausar AU - Anum Latif AU - Samar Abbas Jaffri AU - Syeda Namayah Fatima Hussain AU - Irfan Ahsan AU - Muhammad Rafay AU - Pirih Bhatti Y1 - 2021/02/27 PY - 2021 N1 - https://doi.org/10.11648/j.ijidt.20210601.15 DO - 10.11648/j.ijidt.20210601.15 T2 - International Journal of Infectious Diseases and Therapy JF - International Journal of Infectious Diseases and Therapy JO - International Journal of Infectious Diseases and Therapy SP - 37 EP - 40 PB - Science Publishing Group SN - 2578-966X UR - https://doi.org/10.11648/j.ijidt.20210601.15 AB - Currently, COVID-19 is one of the most pressing healthcare problems across the world. With no definitive pharmacological guidelines, multiple drugs were used to treat critical patients with little success. of Tocilizumab, a monoclonal antibody has shown some role in the treatment of Covid-19 infection. The study was a cross-sectional prospective observational study. It was conducted in the COVID-19 Intensive Care Unit (ICU) of Liaquat National Hospital and Medical College, and National Medical Centre Karachi. The study was conducted from 15th June 2020 to 31st July 2020. Objective of the study was to compare the outcomes of severe to critical COVID-19 patients with established Cytokine release Syndrome (CRS), who received Tocilizumab with the group received Tocilizumab followed by intravenous immunoglobulins (IVIG). Two groups were made with one receiving Tocilizumab alone while the other received IVIG after Tocilizumab. Comparison was then made based on frequency of mortality as well the need of mechanical ventilation and its range of days. In results 4 (15.4%) patients in Tocilizumab only group died while Tocilizumab followed by IVIG treated group had 10 (38.46%) deaths. 20 (76.9%) patients needed mechanical ventilation in Tocilizumab only group while Tocilizumab followed by IVIG treated group consisted of 23 (88.46%) patients. This concludes that the group with only Tocilizumab therapy has better outcome as compare to the group who received both Tocilizumab and intravenous immunoglobulins. VL - 6 IS - 1 ER -
Information
Email: